HLA genotype in patients with acquired haemophilia A

Haemophilia

Volumn 16, Issue 102, 2010, Pages 107-112

  Pavlova, A ^a   Zeitler, H ^a   Scharrer, I ^b   Brackmann, H H ^a   Oldenburg, J ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Acquired haemophilia; Class I; Class II; HLA

Indexed keywords

BLOOD CLOTTING FACTOR 8; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; T LYMPHOCYTE RECEPTOR;

ACQUIRED HEMOPHILIA; ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEMOPHILIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HEMOPHILIA A; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MALE; MIDDLE AGED;

EID: 77953210138     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01976.x     Document Type: Article

References (24)

1. Shapiro SS, Hultin M. Acquired inhibitors to the blood coagulation factors. Semin Thromb Haemost 1975, 1:336-85.
2. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981, 45:200-3.
3. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987, 147:1077-81.
4. Morrison AE, Ludlam CA. Acquired haemophilia and its management. Br J Haematol 1995, 89:231-6.
5. Sallah S, Nguyen NP, Abdallah JM, Hanrahan LR. Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med 2000, 124:730-4.
6. Holme PA, Brosstad F, Tjonnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005, 11:510-5.
7. Bossi P, Cabane J, Ninet J. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998, 105:400-8.
8. Baudo F, Mostarda G, De Cataldo F. Acquired factor VIII and factor IX inhibitors: survey of the Italian Haemophilia Centers (AICE). Register of Acquired factor VIII/IX inhibitors. Haematologica 2003, 88(Suppl. 12):93-9.
9. Kessler CM, Nemes L. Acquired inhibitors to factor VIII. Inhibitors in Patients With Haemophilia 2002, 98-112. Rodriguez-Merchan EC, Lee C. In, eds, Oxford, Science Ltd
10. Pavlova A, az-Lacava A, Zeitler H. Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls. Haemophilia 2008, 14:355-60.
11. Tsuchiya K, Kimura A, Kondo M, Nishimura Y, Sasazuki T. Combination of HLA-A and HLA class II alleles controls the susceptibility to rheumatoid arthritis. Tissue Antigens 2001, 58:395-401.
12. Fernandez O, Fernandez V, Alonso A. DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain. J Neurol 2004, 251:440-4.
13. Buc M, Bucova M, Javor J. Associations between HLA class II alleles and type 1 diabetes mellitus in the Slovak population. Endocr Regul 2006, 40:1-6.
14. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006, 54:1117-21.
15. Sebastiani GD, Morozzi G, Bellisai F. Anti-cofactor autoantibodies in systemic lupus erythematosus: prevalence, clinical and HLA class II associations. Immunol Invest 2008, 37:375-85.
16. Hay CR, Ollier W, Pepper L. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997, 77:234-7.
17. Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997, 77:238-42.
18. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den BM, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995, 73:247-51.
19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
20. Holm S. A simple sequentially rejective multiple test procedure. Holm S. Scand J Stat 1979, 6:65-70.
21. Singer ST, Addiego JE, Reason DC, Lucas AH. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Thromb Haemost 1996, 76:17-22.
22. Reding MT, Wu H, Krampf M. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000, 84:643-52.
23. Jacquemin M, Vantomme V, Buhot C. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003, 101:1351-8.
24. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993, 178:27-47.